Glycemic Variability with Combination Therapy with an SGLT2 Inhibitor and a Combination Drug Incorporating a Glinide and an α-glucosidase Inhibitor

DOI
  • Maruta Chihiro
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine

Bibliographic Information

Other Title
  • SGLT2阻害薬にグリニド薬/α-GI配合剤を併用した際の血糖日内変動

Description

A total of 9 type 2 diabetic patients receiving SGLT2 inhibitors were evaluated for diurnal glycemic variability using CGM when they were given a mitiglinide/voglibose (M/V) combination drug. While SGLT2 inhibitors led to decreases in 24-hr mean glucose levels, addition of M/V significantly improved the indices for glycemic variability. Combination of SGLT2 inhibitors, which could primarily reduce mean glucose by decreasing pre-meal and nighttime glucose, with M/V combination drug, which potently suppresses postprandial glycemic excursions thus narrowing the range of glycemic variability, may represent an ideal therapeutic option, given its benefit for diurnal glycemic variability.

Journal

Details 詳細情報について

  • CRID
    1390283687150236160
  • DOI
    10.15634/j0100_0301_005
  • ISSN
    21887527
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • OpenAIRE
  • Abstract License Flag
    Disallowed

Report a problem

Back to top